Clinical Course of Two Patients with COVID-19 Respiratory Failure After Administration of the Anticancer Small Molecule, RRx-001.

Publication Title

Int Med Case Rep J

Authors

Terese Catherine Hammond, Providence St. Johns Health Center, Santa Monica, CA, USA., John Wayne Cancer Institute, Santa Monica, CA, USA.Follow
Raymond C Lee, Providence St. Johns Health Center, Santa Monica, CA, USA.
Bryan Oronsky
Tony R Reid
Scott Caroen
Tiffany M Juarez
Jaya Gill, Pacific Neuroscience Institute, Santa Monica, CA, USA.Follow
Annie Heng
Santosh Kesari, Providence St. Johns Health Center, Santa Monica, CA, USA., John Wayne Cancer Institute, Santa Monica, CA, USA., Pacific Neuroscience Institute, Santa Monica, CA, USA.Follow

Document Type

Article

Publication Date

1-1-2022

Keywords

california; sjci; pni; covid-19

Abstract

Two critically ill COVID-19 infected patients, who had exhausted all available treatment options, were treated with the small-molecule RRx-001 with subsequent improvement. RRx-001, a first-in-class small molecule with anti-inflammatory, vascular normalizing and macrophage-repolarizing properties, has been safely administered 300+ patients in clinical trials. This is the first report of RRx-001 treatment of COVID-19.

Clinical Institute

Neurosciences (Brain & Spine)

Clinical Institute

Cancer

Specialty/Research Institute

Oncology

Specialty/Research Institute

Infectious Diseases

Specialty/Research Institute

Neurosciences